{"id":"oral-palonosetron","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Dizziness"},{"rate":"5-10%","effect":"Nausea"},{"rate":"<5%","effect":"Vomiting"},{"rate":"<5%","effect":"Diarrhea"},{"rate":"<5%","effect":"Constipation"},{"rate":"<5%","effect":"Fatigue"},{"rate":"<5%","effect":"Injection site reaction"},{"rate":"<5%","effect":"Rash"},{"rate":"<5%","effect":"Pruritus"}]},"_chembl":{"chemblId":"CHEMBL1189679","moleculeType":"Small molecule","molecularWeight":"296.41"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This action is thought to be mediated through the blockade of 5-HT3 receptors on the vagus nerve terminals and in the central nervous system. By blocking these receptors, palonosetron reduces the release of serotonin, which is a key contributor to nausea and vomiting. This mechanism of action is particularly effective in preventing chemotherapy-induced nausea and vomiting.","oneSentence":"Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:44.769Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Prevention of postoperative nausea and vomiting (PONV)"}]},"trialDetails":[{"nctId":"NCT07482891","phase":"PHASE4","title":"An Exploratory Study on Efficacy and Safety of Fosaprepitant and Palonosetron Hydrochloride for Injection in Preventing CINV From Multi-Agent HEC","status":"NOT_YET_RECRUITING","sponsor":"Shanghai 6th People's Hospital","startDate":"2026-03-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":200},{"nctId":"NCT03386617","phase":"PHASE2","title":"AKY15-HK-301_NEPA Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2018-02-27","conditions":"Breast Cancer","enrollment":55},{"nctId":"NCT07442890","phase":"NA","title":"A Cohort Study on the Prevention of Nausea and Vomiting Induced by Concurrent Chemoradiotherapy for Lung Cancer Using Rolapitant and Palonosetron","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04-30","conditions":"Lung Cancer","enrollment":238},{"nctId":"NCT00343460","phase":"PHASE3","title":"APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancer","status":"COMPLETED","sponsor":"Heron Therapeutics","startDate":"2006-06","conditions":"Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":1428},{"nctId":"NCT06952920","phase":"PHASE3","title":"Electroacupuncture for Chemotherapy-Induced GI Symptom Clusters in Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2025-08-21","conditions":"Standard Quadruple Antiemetic Therapy, Electroacupuncture, Chemotherapy-induced Gastrointestinal Symptom Cluster","enrollment":388},{"nctId":"NCT04817189","phase":"PHASE4","title":"Oral Akynzeo® vs Standard of Care in Preventing CINV in High-risk MEC Patients (MyRisk)","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2021-02-01","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":414},{"nctId":"NCT07254416","phase":"PHASE4","title":"A Study on Nausea and Vomiting Caused by T-DXd in Breast Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-12-15","conditions":"Breast Cancer Patients Treated With T-DXd","enrollment":120},{"nctId":"NCT03817970","phase":"PHASE3","title":"Cisplatin Disposition and Kidney Injury","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2019-11-15","conditions":"Nephrotoxicity","enrollment":72},{"nctId":"NCT06200168","phase":"PHASE3","title":"Electroacupuncture for the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients With Breast Cancer","status":"RECRUITING","sponsor":"Jiuda Zhao","startDate":"2024-01-16","conditions":"Electroacupuncture, Olanzapine-contained Four-drug Antiemetic, Nausea and Vomiting","enrollment":370},{"nctId":"NCT05315999","phase":"PHASE2","title":"Protreat-Trial: Prophylactic Antiemetic Treatment of Opioid-induced Nausea and Vomiting (OINV) in Palliative Care","status":"COMPLETED","sponsor":"Gerhild Becker","startDate":"2022-05-03","conditions":"Nausea, Vomiting, Pain","enrollment":30},{"nctId":"NCT01836705","phase":"PHASE1","title":"Effect of SAR302503 on ECG Activity in Patients With Solid Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2013-05","conditions":"Neoplasm Malignant","enrollment":60},{"nctId":"NCT06766825","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults with Post-COVID-19 Condition (PCC)","status":"RECRUITING","sponsor":"Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia","startDate":"2025-02-07","conditions":"Post COVID-19 Condition, Long COVID Syndrome, Persistent COVID-19","enrollment":90},{"nctId":"NCT02116530","phase":"PHASE3","title":"Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2014-08-20","conditions":"Hematopoietic/Lymphoid Cancer, Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":401},{"nctId":"NCT01843868","phase":"NA","title":"Emesis Control Study in Non-Hodgkin Lymphoma Patients Receiving R-CHOP","status":"WITHDRAWN","sponsor":"Australasian Leukaemia and Lymphoma Group","startDate":"2012-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":""},{"nctId":"NCT03204279","phase":"PHASE2","title":"PK/PD Study of Netupitant and Palonosetron in Pediatric Patients for Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2017-08-31","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":67},{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":"Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy","enrollment":627},{"nctId":"NCT03040726","phase":"PHASE2, PHASE3","title":"Netupitant and Palonosetron Hydrochloride in Preventing Chronic Nausea and Vomiting in Patients With Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-05-03","conditions":"Malignant Neoplasm, Nausea, Vomiting","enrollment":53},{"nctId":"NCT05841849","phase":"PHASE4","title":"Efficacy and Safety of Intravenous Versus Oral 5-HT3 Antagonists Combined With NK-1 Receptor Antagonists for the Prevention of CINV in Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-07","conditions":"Breast Cancer, Chemotherapy-induced Nausea and Vomiting","enrollment":1028},{"nctId":"NCT03674294","phase":"PHASE3","title":"Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2015-08-04","conditions":"Gastrointestinal Neoplasms, Chemotherapy-induced Nausea and Vomiting","enrollment":248},{"nctId":"NCT05690802","phase":"NA","title":"The Safety and Effectiveness of Palonosetron Hydrochloride Capsule Was Used to CINV","status":"RECRUITING","sponsor":"Xijing Hospital","startDate":"2022-05-16","conditions":"Nausea and Vomiting","enrollment":1060},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557},{"nctId":"NCT05202275","phase":"PHASE2","title":"The Optimization of Antiemetic Regimen for C-RINV in LA-HNSCCs","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2020-12-01","conditions":"Nausea, Vomiting, Head and Neck Squamous Cell Carcinoma","enrollment":43},{"nctId":"NCT01363479","phase":"PHASE3","title":"An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-07","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":743},{"nctId":"NCT04912271","phase":"PHASE3","title":"Granisetron Transdermal Patch for Prophylaxis of Delayed CINV","status":"UNKNOWN","sponsor":"Fudan University","startDate":"2021-06-10","conditions":"Chemotherapy-induced Nausea and Vomiting (CINV)","enrollment":140},{"nctId":"NCT00553059","phase":"PHASE3","title":"Palonosetron and Dexamethasone With or Without Dronabinol in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy For Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2008-05","conditions":"Chemotherapy-induced Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific","enrollment":62},{"nctId":"NCT04430361","phase":"PHASE2","title":"the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic Chemotherapy","status":"UNKNOWN","sponsor":"Henan Cancer Hospital","startDate":"2018-09-07","conditions":"Tumor, Chemotherapy-induced Nausea and Vomiting","enrollment":120},{"nctId":"NCT03403712","phase":"PHASE3","title":"A Study to Assess the Safety and the Efficacy of IV Fosnetupitant/Palonosetron (260 mg/0.25 mg) Combination Compared to Oral Netupitant/Palonosetron (300 mg/0.5 mg) Combination for the Prevention of CINV in AC Chemotherapy in Women With Breast Cancer","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2018-03-16","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":404},{"nctId":"NCT04201769","phase":"PHASE3","title":"Dexamethasone-sparing Approach Including NEPA Against Emesis Caused by Cisplatin","status":"UNKNOWN","sponsor":"Consorzio Oncotech","startDate":"2016-11-25","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":261},{"nctId":"NCT03862144","phase":"PHASE2","title":"NEPA to Prevent Chemotherapy Induced Nausea and Vomiting in Patients With Breast Cancer","status":"COMPLETED","sponsor":"Consorzio Oncotech","startDate":"2016-05-12","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":150},{"nctId":"NCT03831633","phase":"PHASE4","title":"Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients","status":"UNKNOWN","sponsor":"VIFORFRANCE","startDate":"2018-09-19","conditions":"Oncology","enrollment":426},{"nctId":"NCT03606369","phase":"PHASE2, PHASE3","title":"Effectiveness and Quality of Life Analysis of Palonosetron Against Ondansetron Combined With Dexamethasone and Fosaprepitant in Prevention of Acute and Delayed Emesis Associated to Chemotherapy Moderate and Highly Emetogenic in Breast Cancer.","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2015-11-05","conditions":"Breast Neoplasm, Antineoplastic Agents, Antiemetics","enrollment":560},{"nctId":"NCT03601871","phase":"NA","title":"The Efficacy and Safety of Thalidomide in Preventing CINV Induced by Cisplatin-containing Chemotherapy","status":"UNKNOWN","sponsor":"Yunpeng Liu","startDate":"2018-07-12","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":880},{"nctId":"NCT02517021","phase":"PHASE3","title":"A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-11","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":405},{"nctId":"NCT02557035","phase":"PHASE3","title":"An Efficacy and Safety Study of Intravenous Palonosetron Administered as an Infusion and as a Bolus for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2015-10","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":441},{"nctId":"NCT02388750","phase":"PHASE2","title":"Prospective Study of Palonosetron in Radiation Induced Nausea and Vomiting (RINV)","status":"COMPLETED","sponsor":"Dr. Edward Chow","startDate":"2015-04","conditions":"Nausea, Vomiting","enrollment":96},{"nctId":"NCT00343863","phase":"NA","title":"Dexamethasone and Ondansetron Hydrochloride or Palonosetron Hydrochloride in Preventing Nausea and Vomiting in Patients Receiving Doxorubicin Hydrochloride and Cyclophosphamide For Early Stage Breast Cancer","status":"COMPLETED","sponsor":"University of Washington","startDate":"2006-01","conditions":"Male Breast Cancer, Nausea and Vomiting, Stage I Breast Cancer","enrollment":41},{"nctId":"NCT00381862","phase":"PHASE2","title":"Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX","status":"COMPLETED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-06","conditions":"Colorectal Cancer, Nausea and Vomiting","enrollment":54},{"nctId":"NCT00661674","phase":"NA","title":"Palonosetron and Hydroxyzine to Reduce Opioid Withdrawal","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-04","conditions":"Substance-Related Disorders","enrollment":10},{"nctId":"NCT00895245","phase":"PHASE2","title":"Fosaprepitant Dimeglumine, Palonosetron Hydrochloride, and Dexamethasone in Preventing Nausea and Vomiting Caused by Cisplatin in Patients With Stage III or Stage IV Head and Neck Cancer Undergoing Chemotherapy and Radiation Therapy","status":"TERMINATED","sponsor":"University of Washington","startDate":"2009-02","conditions":"Nausea and Vomiting, Stage III Squamous Cell Carcinoma of the Hypopharynx, Stage III Squamous Cell Carcinoma of the Larynx","enrollment":6},{"nctId":"NCT00687011","phase":"PHASE4","title":"Palonosetron Plus Dexamethasone in Moderately Emetogenic Chemotherapy Induced Nausea and Vomiting (Study P04594)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-10-10","conditions":"Neoplasms, Nausea, Vomiting","enrollment":118},{"nctId":"NCT01370408","phase":"PHASE2","title":"Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients","status":"COMPLETED","sponsor":"Northside Hospital, Inc.","startDate":"2012-02","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":85},{"nctId":"NCT02484911","phase":"PHASE3","title":"Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting","status":"COMPLETED","sponsor":"First Affiliated Hospital of Harbin Medical University","startDate":"2015-05","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":120},{"nctId":"NCT02650479","phase":"PHASE1","title":"Study of the Effects of Intravenous Exenatide on Cardiac Repolarization","status":"COMPLETED","sponsor":"Intarcia Therapeutics","startDate":"2016-01","conditions":"Healthy Adult Male and Female Volunteers","enrollment":82},{"nctId":"NCT02933099","phase":"PHASE3","title":"Aprepitant for the Prevention of Chemotherapy-induced Nausea and Vomiting","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2016-10","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":300},{"nctId":"NCT02203253","phase":"PHASE3","title":"Efficacy of Thalidomide in Preventing Chemotherapy-induced Delayed Nausea and Vomiting","status":"COMPLETED","sponsor":"China Medical University, China","startDate":"2014-07","conditions":"Neoplasms","enrollment":642},{"nctId":"NCT01736917","phase":"PHASE2","title":"Fosaprepitant + 5HT3 Receptor Antagonists + Dexamethasone in Germ Cell Tumors","status":"COMPLETED","sponsor":"Lawrence Einhorn","startDate":"2013-01","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":65},{"nctId":"NCT02445872","phase":"PHASE2","title":"Safety and Efficacy of Aprepitant for CINV in Patients With Lung Cancer Receiving Multiple-day Cisplatin Chemotherapy","status":"UNKNOWN","sponsor":"Zhejiang University","startDate":"2015-12","conditions":"Chemotherapy-Induced Nausea and Vomiting, Lung Cancer","enrollment":80},{"nctId":"NCT00475085","phase":"PHASE3","title":"Prevention of Delayed Nausea A Phase III Double-Blind Placebo-Controlled Clinical Trial","status":"COMPLETED","sponsor":"Joseph Roscoe","startDate":"2006-12","conditions":"Nausea","enrollment":1021},{"nctId":"NCT01111942","phase":"EARLY_PHASE1","title":"A Pilot Study of Induction Chemotherapy Followed by Surgery for Locally Advanced Resectable Head and Neck Cancer","status":"TERMINATED","sponsor":"Southern Illinois University","startDate":"2010-02","conditions":"Head and Neck Cancer","enrollment":4},{"nctId":"NCT02431286","phase":"PHASE4","title":"Palonosetron Associated to Aprepitant in Prophylaxis of PONV","status":"UNKNOWN","sponsor":"Instituto do Cancer do Estado de São Paulo","startDate":"2014-10","conditions":"Postoperative Nausea and Vomiting","enrollment":90},{"nctId":"NCT01339260","phase":"PHASE3","title":"An Efficacy and Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-04","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":1455},{"nctId":"NCT01376297","phase":"PHASE3","title":"A Safety Study of Oral Netupitant and Palonosetron for the Prevention of Nausea and Vomiting","status":"COMPLETED","sponsor":"Helsinn Healthcare SA","startDate":"2011-07","conditions":"Chemotherapy-Induced Nausea and Vomiting","enrollment":413},{"nctId":"NCT02290470","phase":"PHASE2","title":"Olanzapine Against Delayed Nausea and Vomiting in Women Receiving Carboplatin Plus Paclitaxel","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2014-04","conditions":"Nausea, Vomiting","enrollment":81},{"nctId":"NCT02205164","phase":"PHASE2","title":"Palonosetron Plus Aprepitant Versus Palonosetron in Preventing Nausea and Vomiting in Leukemic Patients","status":"UNKNOWN","sponsor":"Associazione Salentina Angela Serra","startDate":"2011-10","conditions":"Chemotherapy Induced Nausea and Vomiting","enrollment":134},{"nctId":"NCT01640340","phase":"NA","title":"Ondansetron Versus Palonosetron Antiemetic Regimen Prior to Highly Emetogenic Chemotherapy(HEC)","status":"COMPLETED","sponsor":"Ohio State University Comprehensive Cancer Center","startDate":"2011-01","conditions":"Malignant Neoplasm","enrollment":40},{"nctId":"NCT00415103","phase":"PHASE4","title":"AMENO-2: Aprepitant Plus Palonosetron Versus Granisetron in the Prevention of Nausea and the Emesis Induced by Chemotherapy in Patients Treated With Haematopoietic Progenitors","status":"COMPLETED","sponsor":"PETHEMA Foundation","startDate":"2006-11","conditions":"Leukemia, Lymphoma","enrollment":196}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Oral palonosetron","genericName":"Oral palonosetron","companyName":"Helsinn Healthcare SA","companyId":"helsinn-healthcare-sa","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Palonosetron works by blocking serotonin 5-HT3 receptors in the body, which helps to prevent nausea and vomiting. Used for Prevention of acute and delayed chemotherapy-induced nausea and vomiting (CINV), Prevention of postoperative nausea and vomiting (PONV).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}